FDA approves Bristol-board-Myers HIV-Droge beschriftenupdate - with updates
Bristol-Myers Squibb Co. (BMY) said Thursday that the U.S. Food and Drug Administration had approved a labeling update for HIV drug Reyataz to include long-term data from the CASTLE Study. Long-term data from the CASTLE Study showed that treatment with Reyataz/r could effectively suppress HIV viral load over 96 weeks in treatment-na‹ve patients.
More: continued here
(c)Autor: Forex Analytics Blog: earn money with Forex
convert this post to pdf.
